Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1

References

• Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras 2013;59:514–24
   PubMed Web of Science ®Google Scholar
• Wong TC, Poon RT. Hepatobiliary malignancies: lessons from Asia. Dig Dis 2013;31:130–7
   PubMed Web of Science ®Google Scholar
• Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon 2005;3:210–15
   PubMed Web of Science ®Google Scholar
• Song P, Feng X, Zhang K. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China. Biosci Trends 2013;7:1–6
   PubMed Web of Science ®Google Scholar
• Chen D, Jiao XL, Liu ZK, et al. Knockdown of PLA2G2A sensitizes gastric cancer cells to 5-FU in vitro. Eur Rev Med Pharmacol Sci 2013;17:1703–8
   PubMed Web of Science ®Google Scholar
• Chekhun VF, Lukyanova NY, Burlaka CA. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to ADMorubicin and cisplatin. Int J Oncol 2013;43:1481–6
   PubMed Web of Science ®Google Scholar
• Chang L, Guo F, Wang Y, et al. MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. Pathol Oncol Res 2014;20:93–8
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58
   PubMed Web of Science ®Google Scholar
• Stacy AE, Jansson PJ, Richardson DR. Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol 2013;84:655–69
   PubMed Web of Science ®Google Scholar
• Ji L, Li H, Gao P, et al. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One 2013;8:e63404
   PubMed Web of Science ®Google Scholar
• Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2013;13:326–46
   PubMed Web of Science ®Google Scholar
• Munoz M, Henderson M, Haber M, Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007;59:752–7
   PubMed Web of Science ®Google Scholar
• Higgins CF, Linton KJ. The ATP switch model for ABC transporters. Nat Struct Mol Biol 2004;11:918–26
   PubMed Web of Science ®Google Scholar
• Pan YZ, Zhou A, Hu Z, Yu AM. Small nucleolar RNA-derived MicroRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Drug Metab Dispos 2013;41:1744–51
   PubMed Web of Science ®Google Scholar
• Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med 2010;16:257–67
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–97
   PubMed Web of Science ®Google Scholar
• Ikemura K, Yamamoto M, Miyazaki S, et al. MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells. Mol Pharmacol 2013;83:399–405
   PubMed Web of Science ®Google Scholar
• Ma MT, He M, Wang Y, et al. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Lett 2013;339:107–15
   PubMed Web of Science ®Google Scholar
• Jiao X, Zhao L, Ma M, et al. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Breast Cancer Res Treat 2013;139:717–30
   PubMed Web of Science ®Google Scholar
• Ling HY, Ou HS, Feng SD, et al. Changes in microRNA profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin Exp Pharmacol Physiol 2009;38:e32–9
   Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001;25:402–8
   PubMed Web of Science ®Google Scholar
• Vander Borght S, Komuta M, Libbrecht L, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008;28:1370–80
   PubMed Web of Science ®Google Scholar
• Guo L, Liu Y, Bai Y, et al. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010;46:1692–702
   PubMed Web of Science ®Google Scholar
• Borel F, Han R, Visser A, et al. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 2012;55:821–32
   PubMed Web of Science ®Google Scholar
• Hou J, Lin L, Zhou W, Wang Z. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011;19:232–43
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang L, Hu J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J Exp Clin Cancer Res 2011;30:55–9
   PubMed Web of Science ®Google Scholar
• Wang F, Xue X, Wei J, et al. hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Br J Cancer 2010;103:567–74
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010;79:817–24
   PubMed Web of Science ®Google Scholar
• Liang Z, Wu H, Reddy S, et al. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 2007;363:542–6
   PubMed Web of Science ®Google Scholar
• Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005;37:1289–95
   PubMed Web of Science ®Google Scholar